GenFleet Overhauls Governance Structure, Calls EGM for Key Incentive and Capital Measures

Genfleet Therapeutics (Shanghai), Inc. Class H ( (HK:2595) ) has provided an update.

GenFleet Therapeutics plans to abolish its Supervisory Committee and transfer its oversight functions to the board’s audit committee, aligning its corporate governance structure with recent amendments to the PRC Company Law and updated regulatory guidelines. The company will seek shareholder approval at an extraordinary general meeting on 9 February 2026, where investors will also vote on new H share option and incentive schemes, a general share repurchase mandate, and related authorizations, marking a comprehensive governance and capital-management overhaul that could affect shareholder rights, management accountability and long-term incentive alignment.

More about Genfleet Therapeutics (Shanghai), Inc. Class H

GenFleet Therapeutics (Shanghai) Inc. is a PRC-incorporated biopharmaceutical company listed in Hong Kong, focused on developing and commercializing therapeutic products. The company operates within China’s regulated capital markets framework and is subject to evolving corporate governance standards under PRC company law and securities regulations.

Average Trading Volume: 749,249

For a thorough assessment of 2595 stock, go to TipRanks’ Stock Analysis page.